193 related articles for article (PubMed ID: 26762414)
1. RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.
Tsubaki M; Takeda T; Yoshizumi M; Ueda E; Itoh T; Imano M; Satou T; Nishida S
Tumour Biol; 2016 Jul; 37(7):9099-110. PubMed ID: 26762414
[TBL] [Abstract][Full Text] [Related]
2. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
[TBL] [Abstract][Full Text] [Related]
3. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
5. Role of the RANK/RANKL Pathway in Multiple Myeloma.
Raje NS; Bhatta S; Terpos E
Clin Cancer Res; 2019 Jan; 25(1):12-20. PubMed ID: 30093448
[TBL] [Abstract][Full Text] [Related]
6. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.
Heider U; Zavrski I; Jakob C; Bängeroth K; Fleissner C; Langelotz C; Possinger K; Hofbauer LC; Viereck V; Sezer O
J Cancer Res Clin Oncol; 2004 Aug; 130(8):469-74. PubMed ID: 15205949
[TBL] [Abstract][Full Text] [Related]
7. Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma.
Łacina P; Butrym A; Humiński M; Dratwa M; Frontkiewicz D; Mazur G; Bogunia-Kubik K
Mol Carcinog; 2021 Feb; 60(2):106-112. PubMed ID: 33283899
[TBL] [Abstract][Full Text] [Related]
8. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
9. RANK-RANKL signalling in cancer.
Renema N; Navet B; Heymann MF; Lezot F; Heymann D
Biosci Rep; 2016 Aug; 36(4):. PubMed ID: 27279652
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
Mori K; Berreur M; Blanchard F; Chevalier C; Guisle-Marsollier I; Masson M; Rédini F; Heymann D
Oncol Rep; 2007 Dec; 18(6):1365-71. PubMed ID: 17982618
[TBL] [Abstract][Full Text] [Related]
11. Inhibition effect of enteropeptidase on RANKL-RANK signalling by cleavage of RANK.
Zhao Y; Jin M; Ma J; Zhang S; Li W; Chen Y; Zhou Y; Tao H; Liu Y; Wang L; Han H; Niu G; Tao H; Liu C; Gao B
FEBS Lett; 2013 Sep; 587(18):2958-64. PubMed ID: 23954298
[TBL] [Abstract][Full Text] [Related]
12. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
[TBL] [Abstract][Full Text] [Related]
13. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
Park B
Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
[TBL] [Abstract][Full Text] [Related]
14. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
15. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
17. RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion.
Shang WQ; Li H; Liu LB; Chang KK; Yu JJ; Xie F; Li MQ; Yu JJ
Oncol Rep; 2015 Dec; 34(6):3007-16. PubMed ID: 26398902
[TBL] [Abstract][Full Text] [Related]
18. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR
J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
